KRAS and colorectal carcinoma: These approaches harmonize in guiding critical treatment decisions for naïve, relapsed or refractory conditions and therefore open new trial/therapy opportunities where regular tissue biopsy is not feasible or there is an urgent need for molecular guided (e.g. in CRC, KRAS/NRAS/BRAFV600E/MSI) treatment decisions (177, 185).